Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.1389
-0.01-9.04%
At close: -
$0.1385
-0.00040-0.29%
After Hours: 4:14 PM EDT
Comments
Loading...
Lyra Therapeutics Analyst Ratings and Price Targets | NASDAQ:LYRA | Benzinga
Lyra Therapeutics Inc has a consensus price target of $8.38 based on the ratings of 6 analysts. The high is $20 issued by BTIG on February 7, 2023. The low is $0.5 issued by Jefferies on May 7, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 14, 2025, August 15, 2024, and May 7, 2024, respectively. With an average price target of $2 between HC Wainwright & Co., there's an implied 1344.04% upside for Lyra Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Jefferies
B of A Securities
BTIG
1calculated from analyst ratings
Analyst Ratings for Lyra Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/14/2025 | Buy Now | 1344.04% | HC Wainwright & Co. | Matthew Caufield37% | $2 → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 08/15/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen57% | — | Reiterates | → Overweight | Get Alert |
| 08/15/2024 | Buy Now | 1344.04% | HC Wainwright & Co. | Matthew Caufield37% | $2 → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen57% | — | Reiterates | → Overweight | Get Alert |
| 05/07/2024 | Buy Now | 1344.04% | HC Wainwright & Co. | Matthew Caufield37% | → $2 | Downgrade | Buy → Neutral | Get Alert |
| 05/07/2024 | Buy Now | 261.01% | Jefferies | Dennis Ding16% | $10 → $0.5 | Downgrade | Buy → Hold | Get Alert |
| 05/06/2024 | Buy Now | — | BTIG | Justin Zelin40% | — | Downgrade | Buy → Neutral | Get Alert |
| 05/01/2024 | Buy Now | 8564.26% | HC Wainwright & Co. | Matthew Caufield37% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 7842.24% | B of A Securities | Jason Gerberry62% | $12 → $11 | Maintains | Buy | Get Alert |
| 03/22/2024 | Buy Now | 8564.26% | HC Wainwright & Co. | Matthew Caufield37% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 10/06/2023 | Buy Now | 10730.32% | BTIG | Justin Zelin40% | → $15 | Assumes | → Buy | Get Alert |
| 10/02/2023 | Buy Now | 8564.26% | HC Wainwright & Co. | Matthew Caufield37% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | Buy Now | 10730.32% | B of A Securities | Jason Gerberry62% | $13 → $15 | Maintains | Buy | Get Alert |
| 08/31/2023 | Buy Now | 8564.26% | HC Wainwright & Co. | Matthew Caufield37% | → $12 | Initiates | → Buy | Get Alert |
| 02/07/2023 | Buy Now | 14340.43% | BTIG | Robert Hazlett37% | $24 → $20 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | 10730.32% | Cantor Fitzgerald | Louise Chen57% | → $15 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Lyra Therapeutics (LYRA) stock?
The latest price target for Lyra Therapeutics (NASDAQ:LYRA) was reported by HC Wainwright & Co. on March 14, 2025. The analyst firm set a price target for $2.00 expecting LYRA to rise to within 12 months (a possible 1344.04% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lyra Therapeutics (LYRA)?
The latest analyst rating for Lyra Therapeutics (NASDAQ:LYRA) was provided by HC Wainwright & Co., and Lyra Therapeutics reiterated their neutral rating.
When was the last upgrade for Lyra Therapeutics (LYRA)?
There is no last upgrade for Lyra Therapeutics
When was the last downgrade for Lyra Therapeutics (LYRA)?
The last downgrade for Lyra Therapeutics Inc happened on May 7, 2024 when HC Wainwright & Co. changed their price target from N/A to $2 for Lyra Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Lyra Therapeutics (LYRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyra Therapeutics was filed on March 14, 2025 so you should expect the next rating to be made available sometime around March 14, 2026.
Is the Analyst Rating Lyra Therapeutics (LYRA) correct?
While ratings are subjective and will change, the latest Lyra Therapeutics (LYRA) rating was a reiterated with a price target of $2.00 to $2.00. The current price Lyra Therapeutics (LYRA) is trading at is $0.14, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.